Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

High-grade serous ovarian cancers (HGSOC) are genomically complex, heterogeneous cancers with a high mortality rate, due to acquired chemoresistance and lack of targeted therapy options. Cyclin-dependent kinase inhibitors (CDKi) target the retinoblastoma (RB) signaling network, and have been success...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor-Harding, Barbie, Aspuria, Paul-Joseph, Agadjanian, Hasmik, Cheon, Dong-Joo, Mizuno, Takako, Greenberg, Danielle, Allen, Jenieke R., Spurka, Lindsay, Funari, Vincent, Spiteri, Elizabeth, Wang, Qiang, Orsulic, Sandra, Walsh, Christine, Karlan, Beth Y., Wiedemeyer, W. Ruprecht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359249/
https://www.ncbi.nlm.nih.gov/pubmed/25557169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359249/
https://www.ncbi.nlm.nih.gov/pubmed/25557169

Ejemplares similares